Therapeutic Solutions International, Inc. Announces the Appointment of Professor David P. Hajjar, Ph.D. to the TSI Scientific Advisory Board

October 27, 2015 08:45 ET

Oceanside, CA — October 27, 2015 — InvestorsHub NewsWire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that David P. Hajjar, Ph.D. has been appointed to our Scientific Advisory Board.

Dr. Hajjar is currently Professor of Biochemistry, at Weill Cornell Medical College and Professor of Pathology and Laboratory Medicine, Pathology and Laboratory Medicine, Weill Cornell Medical College. Professor Hajjar was also a Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics, Pathology and Laboratory Medicine, Weill Cornell Medical College from 1998 – 2014.

“It is our great pleasure to welcome Dr. David Hajjar to our Scientific Advisory Board along with our other distinguished members we previously announced. This board will review and evaluate the resources and infrastructure made available by the Company for its research and development programs. We look forward to the SAB identifying significant emerging regulatory, research and scientific issues and trends and competitive activity, including their potential impacts on any Company programs, plans, or policies relating to its programs and research activities”, said Timothy Dixon, President and CEO.

The principal aim of Dr. Hajjar’s work is to define the mechanisms by which Nitric Oxide (NO) and prostaglandin synthetic pathways interact to alter eicosanoid biosynthesis as well as to investigate the impact of these mediators on atherosclerosis and thrombosis. Over the years, he has defined the roles and mechanisms of these complex signaling interactions in order to gain an understanding of the pathophysiological processes in atherosclerosis using animal models and the consequences of pharmacological interventions.

About Therapeutic Solutions International, Inc.
The Company’s corporate website is Our new products can be viewed on and products can be ordered at

These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


Contact Information

© 2016: Therapeutic Solutions International, Inc., All Rights Reserved | Awesome Theme by: D5 Creation | Powered by: WordPress